Rosiglitazone suppresses lipopolysaccharide-induced matrix metalloproteinase-2 activity in rat aortic endothelial cells via Ras-MEK1/2 signaling.
Matrix metalloproteinases (MMPs) play a key role in the pathogenesis of chronic inflammatory disease, such as atherosclerosis. Among MMPs, MMP-2 is regarded as a major proteinase in atherosclerotic plaque lesions. Peroxisome proliferator activated receptor-gamma (PPARγ) ameliorates oxidative stress and the inflammatory response. The aim of the present study was to evaluate the effect of Rosiglitazone on lipopolysaccharide (LPS)-induced MMP-2 activation as well as its possible mechanism. Primary culture of rat aortic endothelial cells (RAEC) was derived from male Sprague-Dawley rat. MMP-2 activity was assayed by gelatin zymography. Protein expressions were determined by Western Blotting. DNA binding activity of NF-κB was studied with electrophoretic mobility shift assay. LPS-induced MMP-2 activity was inhibited by Rosiglitazone (PPARγ agonist) in the rat aortic endothelial cells (RAEC). LPS-induced MMP-2 activation was diminished due to exposure to NF-κB Activation Inhibitor II (JSH-23) or Ras inhibitor, farnesylthiosalicylic acid (FTS). Further study shows that LPS-induced activation of Phospho-Ras homologue gene family, member A (Rho A) and Phospho-mitogen-activated protein kinase kinase 1/2 (MEK1/2) were significantly inhibited by Rosiglitazone. The activation of NF-κB p65 in the nuclear extract of cells was also significantly suppressed by Rosiglitazone, moreover, the expression of NF-κB p65 was partly activated by GW9662 (PPARγ antagonist). NF-κB DNA binding activity was also demolished by Rosiglitazone. Our data shows that PPARγ agonist, Rosiglitazone suppresses LPS-activated MMP-2 secretion via Ras-MEK1/2 signaling pathways and NF-κB activation. PPARγ agonist and Ras-MEK1/2 pathway may be another potential therapeutic target for the disease induced by chronic inflammation.